Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study. The study was designed to evaluate LEXX’s proprietary DehydraTECH(TM) processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil for potential use in the management of erectile dysfunction. According to the company, the DehydraTECHsildenafil delivered 74% more drug at four minutes than the concentration-matched, generic control formulation with faster and higher overall delivery of sildenafil into the bloodstream evidenced over the course of the study. The most recognizable sildenafil product available currently is Viagra(R), but some users find it slow to act. Lexaria hopes the recent study findings lead to the development of faster, better-acting sildenafil oral formulations. The animal study was conducted at a third-party independent laboratory located in the United States and involved 20 male Sprague-Dawley rats (two groups of 10 rats each) being treated with a single dose of the DehydraTECH-sildenafil and Control-sildenafil formulations.

To view the full press release, visit https://cnw.fm/RCwOn

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids and nicotine by 5 to 10 times, and in some instances with cannabinoids by as much as 27 times; reduce time of onset from one to two hours to minutes; and mask unwanted tastes. The delivery systems are also being evaluated for orally administered, antiviral drugs; nonsteroidal, anti-inflammatory drugs (“NSAIDs”); PDE5 inhibitors; and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.